Company profile
Ironwood Pharmaceuticals, Inc.
NASDAQ: IRWD · Healthcare · Drug Manufacturers - Specialty & Generic
#251 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
78B+FH 85DQ 75GM 70SS 69
v0.1 · 65/100 weight · provisional
↑ operating margin, Piotroski F · ↓ growth stability, Altman-Z
Methodology →Revenue TTM
$361.5M
Rev growth YoY (TTM)
+13.8%
Net income (FY)
$24.0M
Employees
100
as of 2026-08-11
Market cap
$666.7M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$296.2M$296.2M2025
Net income$24.0M$24.0M2025
Operating income$98.5M$98.5M2025
Total assets$396.9M$396.9M2025
Equity-$261.8M-$261.8M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY24
FY24
FY25
FY25
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaborative Arrangements99%
Collaborative arrangement, collaboration and license agreements1%
Royalty0%
Collaborative arrangement, other agreements0%
By geography
North America99%
Europe and Other1%
The read
What is Ironwood Pharmaceuticals, Inc.’s revenue?
Ironwood Pharmaceuticals, Inc. booked $296.2M in FY2025 revenue, growing 143% year over year — faster than most Healthcare companies we track, at a 8.1% net margin.
Peers · Healthcare
HealthStream, Inc.82B+The Beauty Health Company57CEvolus, Inc.59CInogen, Inc.71BRigel Pharmaceuticals, Inc.81B+AngioDynamics, Inc.72BNeighbors
Suffolk →Key facts
CEOThomas A. McCourt
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersBoston, MA
ExchangeNASDAQ: IRWD
Employees100
IPO date2010-02-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.